# DESCRIPTION

## FIELD OF THE INVENTION

- define therapeutic agents

## BACKGROUND OF THE INVENTION

- describe corneal neovascularization

## BRIEF SUMMARY OF THE INVENTION

- introduce lipoxins
- describe therapeutic properties
- outline invention embodiments

## DETAILED DESCRIPTION

- introduce patent scope and limitations
- define terms and abbreviations
- describe lymphangiogenesis and angiogenesis
- introduce lipoxins and their role in inflammation
- describe the investigation of ATLa in regulating angiogenesis
- summarize the results of the investigation

### Results

- describe lipoxinA4 receptor expression in the cornea
- show ATLa reduces neutrophil and macrophage infiltration
- show ATLa reduces inflammatory cytokine expression
- show ATLa impacts the expression of VEGFs and VEGFRs
- evaluate clinical corneal NV and histological assessment of HA and LA

### Discussion

- summarize the role of ATLa in regulating VEGF-A/-C and VEGFR2
- discuss the effects of ATLa on innate immunity and angiogenesis
- explain the importance of neutrophil infiltration in inflammation
- discuss the selective regulation of HA by ATLa
- conclude the potential therapeutic strategy of ATLa in controlling corneal angiogenesis

### Methods

- introduce animal model
- describe suture-induced inflammatory corneal angiogenesis
- outline corneal micropocket assay
- detail ocular administration of compounds
- describe RNA isolation and reverse transcriptase PCR
- outline real-time PCR
- describe isolation of cornea-infiltrating cells
- detail MK/T-1 cell culture and stimulation
- outline immunohistochemical studies
- describe statistics
- motivate treatment of disease states associated with inflammation
- highlight differences between cornea and retina
- discuss limitations of current therapies
- introduce lipoxins as novel therapeutic agents
- define alkenyl
- define alkynyl
- define alkyldiyl
- define alkyleno
- define heteroalkyl
- define cycloalkyl
- define heterocycloalkyl
- define acyclic heteroatomic bridge
- define parent aromatic ring system
- define aryl
- define arylaryl
- define biaryl
- define arylalkyl
- define parent heteroaromatic ring system
- define heteroaryl
- define heteroaryl-heteroaryl and biheteroaryl
- define halogen and haloalkyl
- define alkyl and alkoxy groups
- explain protecting groups
- describe hydroxyl protecting groups
- discuss double bonding and configurational isomers
- explain protecting hydroxyl groups in lipoxin analogs
- discuss stereochemical forms and chiral centers
- describe modifications to lipoxin analogs

### Lipoxins

- define lipoxin analogs
- describe structural formula I
- specify R1 options
- specify R2 and R3 options
- describe structural formula II
- specify R4 options
- specify Y1 and Y2 options
- specify R5 options
- describe structural formula III
- specify R6 options
- describe structural formula IV
- specify R2, R3a, and R3b options
- specify Y1, Y2, Y3, and Y4 options
- specify Y5 and Y6 options
- define lipoxin analogs
- specify structural formula VI
- specify structural formula VII
- specify structural formula VIII
- specify structural formula IX
- specify structural formula X and XI
- define lipoxins
- describe structural formulas
- introduce phenoxy or thiophenoxy substituents
- describe lipoxin analogs
- define R1
- define R2 and R3
- define R4
- define R5
- define R6
- describe therapeutic agents
- describe pharmaceutically acceptable salts
- summarize lipoxin analogs
- define lipoxins
- describe preferred embodiments
- introduce pharmaceutical compositions
- describe synthetic scheme
- define purity of compounds
- define lipoxin analogs
- describe stereoisomers
- define corresponding lipoxin
- define active region
- define recognition site
- define metabolic transformation region
- define detectable label molecule
- define labeled analog
- define inhibits metabolism
- define resists metabolism
- define more slowly undergoes metabolism
- define tissue
- describe pharmaceutical compositions and administration
- define lipoxins
- describe tablet preparation
- describe molded tablets
- describe solid dosage forms
- describe controlled release
- describe sterilization
- describe liquid dosage forms
- describe adjuvants
- describe suspensions
- describe suppositories
- describe topical dosage forms
- describe ointments and creams
- describe powders and sprays
- describe transdermal patches
- describe ophthalmic formulations
- describe parenteral administration
- describe dosage and administration

